November/December 2009, Vol 2, No 7

Business

Health Plan Retention and Pharmacy Costs of Newly Diagnosed Patients with Chronic Kidney Disease in a Managed Care Population
Maureen Kubacki, PharmD, MBA
; Chureen Carter, PharmD, MS
; Alan D.L. Herrera, PharmD
; Jim Wang, PhD
; Janice M. Lopez, PharmD
; Catherine T. Piech, MBA
Stakeholder Perspective by Jeff Januska, PharmD

Regulatory

Quality Improvement Initiatives: The Missed Opportunity for Health Plans
Sara Fernandez-Lopez, PhD
; Barbara Lennert, RN, BSN, MAOM
Stakeholder Perspective by Jeffrey A. Bourret, MS, RPh, FASHP

Clinical

Economic Evaluation of Quality-of-Life Improvement with Second-Generation Antihistamines and Montelukast in Patients with Allergic Rhinitis
Kim R. Saverno, RPh
; Brian Seal, PhD
; Michael J. Goodman, PhD
; Kellie Meyer, PharmD
Stakeholder Perspective by Paul Anthony Polansky, BSPharm, MBA

Editorial

Wellness and the Governing Dynamics of Healthcare Reform
Robert E. Henry

Commentary

Doctors on Healthcare Reform
Betsy McCaughey

Generic Drug Trends

Increases in Drug Utilization and Patent Expirations: A Recipe for Growth of Generics' Market Share, despite Stalling on Biosimilars
Dalia Buffery, MA, ABD

Industry Trends

Management Tools for Molecular Diagnostic Testing: Financial and Clinical Implications
Douglas Moeller, MD